Concert Pharmaceuticals Inc (CNCE.OQ)
18.85USD
23 Apr 2018
$-0.31 (-1.62%)
$19.16
$19.19
$19.40
$18.63
48,133
144,179
$30.70
$11.89
About
Overall
| Beta: | 0.99 |
| Market Cap(Mil.): | $445.15 |
| Shares Outstanding(Mil.): | 23.23 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| CNCE.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 4.67 | 185.04 | 32.78 |
| EPS (TTM): | 4.04 | -- | -- |
| ROI: | 63.73 | -0.74 | 13.21 |
| ROE: | 67.51 | -2.80 | 15.01 |
BRIEF-Concert Pharmaceuticals Inc Files For Mixed Shelf Offering Of Up To $250.0 Million - SEC Filing
* CONCERT PHARMACEUTICALS INC FILES FOR MIXED SHELF OFFERING OF UP TO $250.0 MILLION - SEC FILING Source text (http://bit.ly/2t6Qumw) Further company coverage: (Reuters.Brief@thomsonreuters.com)
BRIEF-Concert Pharmaceuticals Reports Qtrly Loss Per Share $0.26
* CONCERT PHARMACEUTICALS REPORTS YEAR ENDED 2017 FINANCIAL RESULTS
BRIEF-Concert Pharma Says Intends To Complete Evaluation And Advance CTP-692 Into Clinical Development By 2018 End
* CONCERT PHARMACEUTICALS INC SAYS INTENDS TO COMPLETE PRECLINICAL EVALUATION AND ADVANCE CTP-692 INTO CLINICAL DEVELOPMENT BY YEAR-END 2018 Source text for Eikon: Further company coverage:
BRIEF-Concert Pharmaceuticals Initiates Enrollment In Second Cohort Of CTP-543 Trial
* CONCERT PHARMACEUTICALS ANNOUNCES INITIATION OF ENROLLMENT IN SECOND COHORT OF CTP-543 PHASE 2A TRIAL FOR ALOPECIA AREATA
BRIEF-Concert Pharma Says FDA Granted Fast Track Designation To CTP-543
* FDA GRANTS FAST TRACK DESIGNATION TO CONCERT PHARMACEUTICALS’ CTP-543 FOR THE TREATMENT OF ALOPECIA AREATA
BRIEF-Concert Pharmaceuticals Announces Patent Trial And Appeal Board Did Not Institute PGR Proceeding
* CONCERT PHARMACEUTICALS ANNOUNCES PATENT TRIAL AND APPEAL BOARD DID NOT INSTITUTE PGR PROCEEDING Source text for Eikon: Further company coverage:
BRIEF-Concert Pharmaceuticals Announces Appointment Of Marc Becker As CFO
* CONCERT PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF MARC BECKER AS CHIEF FINANCIAL OFFICER
BRIEF-Concert Pharmaceuticals reports Q3 earnings per share $5.61
* Concert Pharmaceuticals reports third quarter 2017 financial results and provides company update
BRIEF-Concert Pharmaceuticals announces completion of enrollment in First Cohort of CTP-543 phase 2a trial
* Concert Pharmaceuticals Inc announces completion of enrollment in First Cohort of CTP-543 phase 2a trial
Estimates